ReviewApplied microbiology and biotechnology2022
Ganoderma immunomodulatory proteins: mushrooming functional FIPs.
Review in Applied microbiology and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- An Amazonian Ganoderma isolate as a source of antioxidant proteins: Influence of submerged fermentation conditions on mycelial architecture and bioactivity.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Impact of Submerged Fermentation Parameters on Proteins Extracted fromMicroorganisms · 2026Article
- Immunomodulatory Effects ofCurrent issues in molecular biology · 2025Review
- Article
- Unlocking the therapeutic potential of bioactive compounds in3 Biotech · 2025Review
- Characterization and Functional Analysis of a Novel Fungal Immunomodulatory Protein Gene fromInternational journal of molecular sciences · 2025Article
- Identification a novel Ganoderma FIP gene from Ganoderma capense and its functional expression in Pichia pastoris.World journal of microbiology & biotechnology · 2024Article
- In Silico functional and phylogenetic analyses of fungal immunomodulatory proteins of some edible mushrooms.AMB Express · 2022Article
- Safety assessment of the fungal immunomodulatory protein fromToxicology reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal immunomodulatory protein (FIP) is a novel functional protein family with specific immunomodulatory activity identified from several macro-fungi. A variety of biological activities of FIPs have been reported, such as anti-allergy, anti-tumor, mitogenic activity, and immunomodulation. Among all known FIPs, the firstly discovered FIP was isolated from Ganoderma lucidum, and most FIP members were from Ganoderma genus. Compared with other FIPs, Ganoderma FIPs possess some advantageous bioactivities, like stronger anti-tumor activity. Therein, gene sequences, protein structural features, biofunctions, and recombinant expression of Ganoderma FIPs were summarized and addressed, focusing on elucidating their anti-tumor activity and molecular mechanisms. Combined with current advances, development potential and application of Ganoderma FIPs were also prospected. KEY POINTS: • More than a dozen of reported FIPs are identified from Ganoderma species. • Ganoderma immunomodulatory proteins have superior anti-tumor activity with promising prospects and application. • Current review comprehensively addresses characterization, biofunctions, and anti-tumor mechanisms of Ganoderma FIPs.
Indexed as
Identifiers
35348851What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.